Accelerating access to vaccines through the ACT Accelerator & COVAX

WHO Executive Board
18 January 2021
State of Vaccines: key numbers (data as of 18 January 2021)

• 1st vaccination programme started **42 days ago**\(^1\) (23 days in EU)

• To date, **40 million doses of vaccine** have been administered
  • 95% have been administered in top 10 countries
  • At least 7 different vaccines (3 platforms) have been administered\(^2\)

• Vaccination has **started in 50 countries**
  • Including 40 HICs; 8 UMICs; 1 LMIC; 1 LIC

1. Dec. 8, 2020 in the UK (Pfizer); Dec. 5, 2020 in Russia (Gamaleya)
2. Pfizer, Moderna, Gamaleya, Sinovac, Sinopharm, Serum Institute of India, Bharat Biotech
State of Vaccines: geographies & products (data at 18 January 2021)

Total COVID-19 vaccine doses/100 people
NOTE: single doses, not the total number of people vaccinated

Number of countries using specific vaccine(s)
NOTE: 39 countries are using 1 vaccine; 11 countries using 2 vaccines

1 NOTE: AZ/UK is approved by an SRA but for batch by batch release
COVAX Facility is in a strong position to vaccinate, with the aim of initiating deliveries in February

**COVAX Deals**
- 2 billion doses
- 6 products
- 5 producers
- >1 B in options

**COVAX Donations**
- *Principles for sharing COVID-19 Vaccine Doses with COVAX*
  - published 18 Dec 2020
  - discussion ongoing with potential donors

COVAX Participant Countries are ready to begin administering COVID-19 vaccines

Country Readiness

• 88 of 92 AMC countries submitted Vaccine Request Form

• 124 country readiness assessments (incl. 64 AMC countries)

Regulatory Pathways for rapid in-country import & emergency use authorizations

Indemnification & Liability

• *model indemnification language* established (8 January 2021)

• *no-fault compensation mechanism* developed (end-January 2021)
Crucial importance of expediting regulatory review of key COVAX portfolio products (approximately 2 billion of the 3 billion doses COVAX aims to contract will be ready for delivery in 2021\(^1\))

\(^1\) Data as of 7 January 2021
Crucial actions to support COVAX Facility rollout in February

1. **WHO Regulatory Review:**
   - expedite full data & review for priority contracted products (i.e. SII/AZ; SK Bio/AZ)
   - process full dossiers submitted to date on other products (i.e. Sinopharm, Sinovac)

2. **COVAX Portfolio:**
   - immediately expand to include approved mRNA vaccine(s)
   - rapidly explore potential early supply from other advanced candidates

3. **Dose-Sharing:** initiate donations to COVAX from key countries with bilateral-deals

4. **In-Country Readiness:** ensure regulatory authorizations and legal frameworks for indemnification & no-fault compensation are in place

**COVAX & ACT-A in 2021:** 3 big shifts will drive our priorities to accelerate development & equitable access to new COVID-19 tools

<table>
<thead>
<tr>
<th>From:</th>
<th>To:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primarily supply side problem assuming strong demand for all tools</td>
<td>Universal &amp; unmet demand for vaccines with suboptimal demand for diagnostics/Tx</td>
</tr>
<tr>
<td>Stable virus with uniform epi &amp; response globally</td>
<td>Evolving viral mutations and variable epidemiology, urgency &amp; response</td>
</tr>
<tr>
<td>Strong global multilateral commitment of all key actors</td>
<td>Escalating bilateral deals and suboptimal investment in global solutions</td>
</tr>
</tbody>
</table>

A ‘refreshed & prioritized’ ACT-A Strategy & Needs for 2021 will be presented to the ACT-A Facilitation Council on 9 February 2021
Accelerating COVID-19 vaccine rollout globally

- COVAX aims to start deliveries in February
- Countries with bilateral deals are urged to be transparent with COVAX, prioritize COVAX’s ‘place in the queue’ & dose share
- Producers are urged to rapidly provide full regulatory data to WHO, prioritize COVAX supply contracts & facilitate donations/dose-sharing
- Countries introducing vaccines are urged to only use products that meet rigorous international standards for safety, efficacy & quality (e.g. WHO EUL)
- Donors are urged to fully finance COVAX procurement & delivery and R&D to optimize products and address variants